Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab
Rosemary Harrup(University of Tasmania), John F. Seymour(The Royal Melbourne Hospital), Carolyn Owen(University of Calgary), Maria Thadani‐Mulero(Roche (United Kingdom)), Arnon P. Kater(Amsterdam University Medical Centers), Brenda Chyla(AbbVie (United States)), Michelle Boyer(Amgen (United States)), Marcus Lefebure(Peter MacCallum Cancer Centre), Barbara Eichhorst(University of Cologne), Hyun Yong Jin(Scripps Research Institute), Rosemary Millen(Royal Netherlands Academy of Arts and Sciences), Yi Meng Chang(Roche (Canada)), Yanwen Jiang
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k